Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 176,900 shares of the stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the completion of the sale, the chief operating officer now owns 668,680 shares of the company's stock, valued at approximately $7,903,797.60. The trade was a 20.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Eric Venker also recently made the following trade(s):
- On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
- On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00.
- On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.
- On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00.
Roivant Sciences Stock Up 3.5 %
Shares of ROIV traded up $0.40 during trading on Tuesday, reaching $11.83. 4,205,813 shares of the company traded hands, compared to its average volume of 5,754,317. The stock has a 50-day simple moving average of $11.91 and a 200-day simple moving average of $11.55. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06. The stock has a market cap of $8.61 billion, a PE ratio of 2.09 and a beta of 1.25.
Wall Street Analysts Forecast Growth
ROIV has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 19th. Bank of America increased their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research note on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $17.93.
View Our Latest Stock Report on ROIV
Institutional Trading of Roivant Sciences
Several institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in Roivant Sciences during the second quarter worth $34,000. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences in the 3rd quarter valued at $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences during the 2nd quarter worth about $36,000. US Bancorp DE boosted its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares during the period. Finally, Quarry LP acquired a new position in Roivant Sciences in the 2nd quarter valued at about $53,000. Institutional investors and hedge funds own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
